Showing 1 posts of 1 posts found.
Savient Pharmaceuticals has reported that some production batches of Krystexxa, its recently-approved second-line treatment for gout, have failed to meet …
InnoScot highlights NHS Scotland’s progress towards net zero healthcare
NHS England approves delayed-release treatment for rare kidney disease
Product value to pathway impact: What the CVD Modern Service Framework means for pharma
Functional lung imaging offers new possibilities for respiratory care
Five Facts about cardiovascular disease